Merz, Maximilian, Jauch, Anna, Hielscher, Thomas, Bochtler, Tilmann, Schoenland, Stefan Olaf, Seckinger, Anja, Hose, Dirk, Bertsch, Uta, Neben, Kai, Raab, Marc Steffen, Hillengass, Jens, Salwender, Hans, Blau, Igor Wolfgang, Lindemann, Hans-Walter, Schmidt-Wolf, Ingo G. H., Scheid, Christof, Haenel, Mathias, Weisel, Katja C. and Goldschmidt, Hartmut (2018). Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. Blood Adv., 2 (1). S. 1 - 10. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 2473-9537

Full text not available from this repository.

Abstract

We investigated subclonal cytogenetic aberrations (CA) detected by interphase fluorescence in situ hybridization (iFISH) in patients with newly diagnosed multiple myeloma (MM) enrolled in the Haemato Oncology Foundation for Adults in the Netherlands (HOVON)-65/German-Speaking MM Group (GMMG)-HD4 phase 3 trial. Patients were either treated with 3 cycles of vincristine, Adriamycin, and dexamethasone or bortezomib, Adriamycin, and dexamethasone and then thalidomide or bortezomib maintenance after tandem autologous transplantation. Subclones were defined either by presence of different copy numbers of the same chromosome loci and/or CA present in at least 30% less and maximally 2/3 of cells compared with the main clone CA. Patients with subclones harbored more frequently high risk (31.0%) or hyperdiploid main clone aberrations (24.8%) than patients with t(11; 14) in the main clone (10.1%). Gains and deletions of c-MYC were the only CA that occurred more frequently as subclone (8.1%/20.5%) than main clone (6.2%/3.9%, respectively). Treatment with bortezomib completely overcame the negative prognosis of high-risk CA in patients without subclones, but not in patients with additional subclonal CA. High-risk patients treated without bortezomib showed dismal outcome whether subclones were present or not. Cytogenetic heterogeneity defined by subclonal CA is ofmajor prognostic significance in newly diagnosed MM patients treated with bortezomib within the HOVON-65/GMMG-HD4 trial.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Merz, MaximilianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jauch, AnnaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hielscher, ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bochtler, TilmannUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schoenland, Stefan OlafUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Seckinger, AnjaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hose, DirkUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bertsch, UtaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Neben, KaiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Raab, Marc SteffenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hillengass, JensUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Salwender, HansUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Blau, Igor WolfgangUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lindemann, Hans-WalterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schmidt-Wolf, Ingo G. H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scheid, ChristofUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Haenel, MathiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Weisel, Katja C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goldschmidt, HartmutUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-199024
DOI: 10.1182/bloodadvances.2017013334
Journal or Publication Title: Blood Adv.
Volume: 2
Number: 1
Page Range: S. 1 - 10
Date: 2018
Publisher: AMER SOC HEMATOLOGY
Place of Publication: WASHINGTON
ISSN: 2473-9537
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
IN-SITU HYBRIDIZATION; HIGH-RISK PATIENTS; DELETION 17P; HOVON-65/GMMG-HD4 TRIAL; TRANSPLANTATION; BORTEZOMIB; EVOLUTION; DEXAMETHASONE; TRISOMIES; SUBGROUPMultiple languages
HematologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/19902

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item